completed2023-12-15D series

Letermovir

Neues Anwendungsgebiet: CMV-Erkrankung, Prophylaxe nach Nierentransplantation

Open official case page ↗

Brand: Prevymis
Manufacturer: MSD Sharp & Dohme GmbH

G-BA action

final resolution

2024-08-06

Arzneimittel-Richtlinie/Anlage XII: Letermovir (Neues Anwendungsgebiet: CMV-Erkrankung, Prophylaxe nach Nierentransplantation) – Therapiekosten

Evidence-checked summary

The G-BA issued a final resolution on 2024-08-06. The official page states that it took effect as follows: 08.08.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.

Open G-BA decision →Open official action source ↗

Final benefit result

G-BA result by patient group

Open decision 6634 →

Patient group

CMV-seronegative Erwachsene, die eine Nierentransplantation von einem CMV-seropositiven Spender erhalten haben, zur Prophylaxe einer CMV-Erkrankung

Added benefit not proven

Comparator
Ganciclovir oder Valganciclovir

Open official result PDF ↗

Official case record

What happened, in source order

No inferred stages

Consultation record

Oral hearing and Wortprotokoll

1 hearing

2024-04-22

142 parsed turns

Oral hearing: Letermovir (Neues Anwendungsgebiet: CMV-Erkrankung, Prophylaxe nach Nierentransplantation)

Official Wortprotokoll · 14 pages

Open official source PDF ↗Read transcript turns →

IQWiG comparison

Assessment record versus G-BA action

1 reference

IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.

A23-137

matched

Letermovir (CMV prophylaxis after kidney transplant) – Benefit assessment according to §35a Social Code Book V

Official assessment PDF · 82 pages

Open structured assessment →Open official PDF ↗

G-BA decisions

Distinct actions and documents

2 decision

2024-06-06

final resolution

Arzneimittel-Richtlinie/Anlage XII: Letermovir (Neues Anwendungsgebiet: CMV-Erkrankung, Prophylaxe nach Nierentransplantation)

The G-BA found no proven added benefit for CMV-seronegative Erwachsene, die eine Nierentransplantation von einem CMV-seropositiven Spender erhalten haben, zur Prophylaxe einer CMV-Erkrankung. The appropriate comparator was Ganciclovir oder Valganciclovir. The G-BA issued a final resolution on 2024-06-06. The official page states that it took effect as follows: 06.06.2024. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.

4 official documents · 4 cited claims

Open decision →

2024-08-06

final resolution